{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:50:59Z","timestamp":1791661859322,"version":"4.3.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.dmd.2026.100411","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:35:42Z","timestamp":1789688142000},"page":"100411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of nonspecific binding to membrane vesicles on unbound IC50 estimation for P-glycoprotein and breast cancer resistance protein inhibitors and implications for drug-drug interaction risk assessment"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2318-5218","authenticated-orcid":false,"given":"Renjie","family":"Zhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Moulton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Tallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelby","family":"Hullett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3515-1821","authenticated-orcid":false,"given":"Sangwoo","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mohutsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4645-0763","authenticated-orcid":false,"given":"Maria","family":"Posada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2016-9930","authenticated-orcid":false,"given":"Bridget","family":"Morse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6097-2651","authenticated-orcid":false,"given":"Chester","family":"Costales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.dmd.2026.100411_bib5","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/psp4.12672","article-title":"Quantitative prediction of breast cancer resistant protein mediated drug-drug interactions using physiologically-based pharmacokinetic modeling","volume":"10","author":"Costales","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100411_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100056","article-title":"Significance of gut breast cancer resistance protein versus organic anion transporting polypeptide 2B1 inhibition on rosuvastatin clinical drug-drug interactions","volume":"53","author":"West","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmd.2026.100411_bib7","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.xphs.2023.01.014","article-title":"Translatability of in vitro inhibition potency to in vivo P-glycoprotein-mediated drug interaction risk","volume":"112","author":"Lazzaro","year":"2023","journal-title":"J Pharm Sci"},{"issue":"7","key":"10.1016\/j.dmd.2026.100411_bib8","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1124\/dmd.112.050542","article-title":"Application of receiver operating characteristic analysis to refine the prediction of potential digoxin drug interactions","volume":"41","author":"Ellens","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2026.100411_bib9","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1124\/dmd.121.000807","article-title":"Selection of an optimal in vitro model to assess P-gp inhibition: comparison of vesicular and bidirectional transcellular transport inhibition assays","volume":"50","author":"Yabut","year":"2022","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.dmd.2026.100411_bib10","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1124\/dmd.30.12.1497","article-title":"The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties","volume":"30","author":"Austin","year":"2002","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.dmd.2026.100411_bib11","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1124\/dmd.121.000430","article-title":"Comparative hepatic and intestinal efflux transport of statins","volume":"49","author":"Deng","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.dmd.2026.100411_bib12","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1124\/dmd.108.021410","article-title":"Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin","volume":"36","author":"Kitamura","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2026.100411_bib13","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1124\/dmd.105.007534","article-title":"ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein","volume":"34","author":"Huang","year":"2006","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.dmd.2026.100411_bib14","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/01.fpc.0000230113.03710.34","article-title":"In-vitro transport characteristics discriminate wild-type ABCB1 (MDR1) from ALA893SER and ALA893THR polymorphisms","volume":"16","author":"Schaefer","year":"2006","journal-title":"Pharmacogenet Genomics"},{"issue":"23","key":"10.1016\/j.dmd.2026.100411_bib15","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Yung-Chi","year":"1973","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100411_bib16","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1128\/AAC.02931-15","article-title":"Inhibitory potential of antifungal drugs on ATP-binding cassette transporters P-glycoprotein, MRP1 to MRP5, BCRP, and BSEP","volume":"60","author":"Lempers","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.dmd.2026.100411_bib17","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0090-9556(25)08404-1","article-title":"The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations","volume":"24","author":"Obach","year":"1996","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2026.100411_bib18","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1124\/dmd.31.5.606","article-title":"Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P450 2D6: implications for relating in vitro inhibition data to in vivo drug interactions","volume":"31","author":"Margolis","year":"2003","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2026.100411_bib19","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1074\/jbc.M115.706523","article-title":"Phosphatidylethanolamine is a key regulator of membrane fluidity in eukaryotic cells","volume":"291","author":"Dawaliby","year":"2016","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.dmd.2026.100411_bib20","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1124\/jpet.106.119289","article-title":"Cholesterol potentiates ABCG2 activity in a heterologous expression system: improved in vitro model to study function of human ABCG2","volume":"321","author":"Pal","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"20","key":"10.1016\/j.dmd.2026.100411_bib21","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1021\/acs.jpcb.1c02436","article-title":"Effects of cholesterol on the partitioning of a drug molecule in lipid bilayers","volume":"125","author":"Yang","year":"2021","journal-title":"J Phys Chem B"},{"issue":"11","key":"10.1016\/j.dmd.2026.100411_bib22","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1021\/acs.jpcb.9b11005","article-title":"Cholesterol reduces partitioning of antifungal drug itraconazole into lipid bilayers","volume":"124","author":"Poojari","year":"2020","journal-title":"J Phys Chem B"},{"key":"10.1016\/j.dmd.2026.100411_bib23","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ejps.2018.07.004","article-title":"Concentration-dependent plasma protein binding: expect the unexpected","volume":"122","author":"Nation","year":"2018","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.dmd.2026.100411_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105593","article-title":"Inhibition of ABCG2\/BCRP-mediated transport-correlation analysis of various expression systems and probe substrates","volume":"156","author":"Safar","year":"2021","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"10.1016\/j.dmd.2026.100411_bib25","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1111\/j.1755-5922.2011.00290.x","article-title":"The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins","volume":"30","author":"Hua","year":"2012","journal-title":"Cardiovasc Ther"},{"issue":"9","key":"10.1016\/j.dmd.2026.100411_bib26","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.xphs.2017.04.004","article-title":"Intestinal drug interactions mediated by OATPs: a systematic review of preclinical and clinical findings","volume":"106","author":"Yu","year":"2017","journal-title":"J Pharm Sci"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562600680X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562600680X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:28:12Z","timestamp":1791660492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009095562600680X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S009095562600680X"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100411","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of nonspecific binding to membrane vesicles on unbound IC50 estimation for P-glycoprotein and breast cancer resistance protein inhibitors and implications for drug-drug interaction risk assessment","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100411","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100411"}}